Progression-free survival of 126 patients with multiple myeloma after ASCT as a function of ALC recovery at day 15.

Median progression-free survival for patients with an ALC greater than or equal to 500 cells/μL was 16 months versus 8 months for patients with an ALC < 500 cells/μL (P < .0003).